Robin mansukhani
ceo Deciduous Therapeutics
Robin Mansukhani is the CEO and Co-Founder of Deciduous Therapeutics, a venture-backed biotech pioneering novel immunotherapies to treat age-related diseases, including fibrosis. Under his leadership, Deciduous is advancing a new class of antifibrotic therapies aimed at reprogramming the immune system to selectively eliminate pathogenic senescent cells implicated in IPF and other chronic diseases. Robin previously co-founded and served as CEO of Alzeca Biosciences and has advised early-stage biotech companies in the aging and CNS space. He holds a B.S. in Biochemistry from Case Western Reserve University and has spoken at leading forums including TEDx.
Seminars
Wednesday 2nd December 2026
Targeting Senescent Cells & Injury Resolution Pathways to Remove Barriers to Fibrosis Reversal
4:15 pm
- Understanding how senescent cells perpetuate pro-fibrotic signaling & prevent resolution even after initial injury removal
- Evaluating senolytic & senostatic approaches to eliminate or reprogram senescent cell populations in fibrotic tissues
- Assessing early clinical evidence for senescence-targeted therapies in promoting fibrosis regression across multiple organs
